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Effects of Beta-Adrenergic Blockade on the Natural Progression of
Myocardial Infarct Size and Compensatory Hypertrophy
ROBERT A. SLUTSKY, MD, FACC, WALLACE W. PECK, MD
San Diego, California
Using contrast-enhanced computed tomography, the ef-
fects of beta-adrenergic blockade were assessed on ex-
perimentally produced myocardial infarcts in dogs eval-
uated serially over the course of approximately I month.
Infarct size, initial perfusion defect (jeopardized seg-
ment) and noninfarcted muscle mass were studied in two
groups of conditioned mongrel dogs. Group I (n = 11)
served as the control group and Group 2 (n = 10) was
pretreated with propranolol (2 mg/kg), Each animal in
the propranolol-treated group was given identical amounts
of the agent twice daily for 7 days after coronary occlu-
sion. Both groups developed increases in the nonin-
farcted muscle mass of the left ventricle (compensatory
Quantification of myocardial infarct size is of prognostic
importance in patients with acute ischemic damage (1, 2).
There have been a number of attempts to examine infarct
size during therapeutic interventions (3). To a large extent,
limitation of techniques for estimating infarct size, lack of
knowledge of the natural progression of infarct size in vivo
and the difficulty of differentiating between acute and long-
term modifications in infarct size have made interpretation
of the utility of these intervention studies unclear.
Recent implementation of contrast-enhanced computed
tomography has allowed an assessment of myocardial infarct
size . The abilit y of tomography to detect myocardial in-
farction has been evident since the report of Adams et al.
(4) . Since then , several studies (5- 8 ) have examined the
ability of computed tomography to detect and quantitate the
size of myocardial infarcts in ex vivo and in vivo experi-
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hypertrophy). The mean increase averaged 19.8% over
30 days when the two groups were included together.
Infarct size was smaller in the propranolol-treated group,
and averaged 28% less (p < 0.05) than that of the control
group 30 days after initial myocardial infarction.
Thus, pharmacologic interventions were shown by
computed tomography to alter the size of an acute ex-
perimental myocardial infarct, particularly when ex-
amined over the time course of infarct healing. More-
over, compensatory hypertrophy occurred in both the
control and propranolol-treated groups.
(J Am CoIl CardioI1985;5:JJ32-7)
mental models and, although specific protocols have dif-
fered, the findings indicate that X-ray transmission and to-
mography is a relatively accurate method for measuring
infarct size. Moreover, we have validated tomographic in-
farct sizing in acute , chronic and reperfused infarcts and
found accurate data avail able from images derived from each
group (8-10). In addition, we recently studied (10) dogs
serially over the course of I month after occlusion of the
left anterior descending coronary artery using contrast-en-
hanced computed tomography. Computed tomographic scans
were obtained acutely (20 minutes after coronary occlusion)
and then at multiple time periods until sacrifice approxi-
mately 1 month later. We found that infarct size increased
at 4 days when compared with initial perfusion defect , then
progres sively decreased . The initial perfusion defect over-
estimated the eventual infarct size at I month by 33 ± 15%.
Noninfarcted left ventricular muscle mass increased signif-
icantly (27 ± 7% greater at I month compared with day
0) over time, presumably representing compensatory left
ventricular hypertrophy. The left ventricular muscle mass
at necropsy correlated well (r = 0 .94 , P < 0.(01) with the
tomographic muscle mass just before sacrifice of the dog .
Thus , the purposes of the current study were to evaluate
the effect s of beta-adrenergic blockade on computed tom-
ographic estimates of infarct size over time and to examine
the associated changes in compensatory hypertrophy of the
noninfarcted residual muscle.
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Methods
Study 1
Experimental model. The experiments were initially
conducted in 26 conditioned mongrel dogs weighing from
22 to 35 kg. Each animal was anesthetized with intravenous
sodium pentobarbital (25 rug/kg body weight) before a left
thoracotomy was performed. A hydraulic occluder was placed
around the proximal left anterior descending coronary ar-
tery. The catheter was burrowed subcutaneously and exter-
nalized. An injectioncatheter was placed into the left atrium
and also burrowed subcutaneously. The wound was asep-
tically closed and the dog allowed to recover. Control com-
puted tomographic scans were obtained 4 to 7 days after
surgery in all animals to ensure that none developed in-
farction during the preparation of the initial experimental
model. In addition, enzymatic analysis during the first 24
to 48 hours after the preparation confirmed the later scan
data.
Three or more days after the control scans were obtained,
each animal was premedicatedwith subcutaneous morphine
sulfate (2.5 to 3.0 mg/kg) and intramuscular procainamide
(150 mg). The dog was anesthetized with sodium pento-
barbital (25 rng/kg) intravenously, paralyzed with succi-
nylcholine (1.0 to 1.5 rng/kg) intravenously and ventilated
witha Harvardrespirator(14 to 16breaths/min, tidal volume
12 to 15 cc/kg). The hydraulic occluder was inhated with
the animal in the scanner. Scanning was performed im-
mediately after coronary occlusion and at 3 to 4, 7 to II
and 28 to 32 days after occlusion. After the final scan, the
animal was killed and postmortem examination was
performed.
The dogs were randomly separated into two groups: group
I served as a control and group 2 was given 2 mg/kg of
propranolol hydrochloride (Ayerst Laboratories) intrave-
nously 10minutes beforecoronary occlusion and then twice
daily for 7 days after occlusion. Twenty-one animals sur-
vivcd for the duration of the experiment (II in group I and
10 in group 2).
Computed transmission tomographic analyses. All
studies were performed on a Technicare 2020 whole-body
scanner with an individual scan time of 2 seconds. The
scanning technique was set at 120 kVp, 100 mA, 10 mm
slice thickness and a 25 ern scanning circle. The scanner
has 720 stationary detectors. All images were reconstructed
utilizing the same reconstruction algorithm with a 512 x
512 matrix.
On the day of infarction. an intravenous infusion of me-
glumine sodium diatrizoate (76%) was started 20 minutes
after coronary occlusionof the left anteriordescendingcoro-
nary artery (above the first diagonal branch) at a rate of 6
cc/min (lasting for 10 minutes. total volume = 60 ml) using
a Harvard infusion pump. For orientation purposes. a set
of (ungated) scans were obtained from the apex to the base
of the left ventricle (perpendicular to the long axis of the
ventricle) at 10 minutes into the infusion period. The con-
trast infusion was then stopped. Ten to 15 minutes after
cessation of the contrast infusion, a series of ungated scans
was again obtained from the apex to the base of the heart.
On every scan day thereafter, the same protocol was fol-
lowed. All scans were obtained during held inspiration. The
scans taken during the infusion defect and the scans obtained
on subsequent days were used to quantify the contrast en-
hancementof the infarct itself and to quantitate infarct size.
Postmortem examination. Immediately after the final
scans, each animal was killed and the heart was removed
and sectioned at 1 em intervals from apex to base along the
major axis of the left ventricle. The slices were incubated
in a I% solution of triphenyltetrazolium chloride (Sigma
Chemical), in phosphate buffer for IO minutes at 37°C(11).
The endocardialand epicardial bordersof the left ventricular
wall and the visible area of infarction were traced onto clear
film overlays. Analysis of these overlays is described later.
Data analysis. IfzJarct size measurement. Each set of
images (apex to base) was printed on transparent film along
with spatial calibration markers. In each animal, on the
initial occlusion day SC8~S, one region from each slice was
definedas the" perfusiondefect." This consisted of an area
of lower attenuationcompared with the normally enhancing
myocardium on images obtained after the infusion of con-
trast medium. On the scans obtained on later days, a second
region in addition to the area of low attenuation was defined
as the " enhanced defect," which represented the area of
myocardium demarcated by the outer margin of a region of
delayed contrast enhancement at the periphery of the infarct
zone. On delayed scans. the periphery of the infarct has
greater enhancement than the normal myocardium and cen-
ter of the infarct (12). This region of delayed enhancement
corresponds to the region of accumulation of technetium-
99m pyrophosphate in hearts with infarction (12). We have
demonstrated the superior precision of infarct estimates when
the contrast-enhanced segment is included (13). In our ex-
perience. the best representation of this was on the ungated
imagesobtained at 10minutes after cessation of the infusion
(20 minutes from the start of the contrast infusion).
Volume of the jeopardized and infarcted regions of the
left ventricl e was determined by planimetry utilizing a Hew-
lett-Packard computer/digitizer (9825/9874A) system with
manual tracing of the "perfusion defect" and "enhanced
defects." respectively. The computer then calculated the
area contained within the closed loop. The ventricular slices
were each assumed to be cylindrical. The volume of the
scan-calculated size or perfusion defect was obtained by
summing the volume of infarcted tissue (each slice was I
em) for each individual slice from the apex to the base of
the heart. The postmortem overlays were similarly deter-
mined by planimetry and the same geometric assumptions
were made. We found that infarct size assessed by computed
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tomography correlated well with postmortem values for all
of the animals initially entered into the study (r = 0.91)
(SEE = 2.1 g) .
The variability of this technique in our laboratory when
the slices are retracted and redigitized is ± 3.5% (8). More-
over, when each scan is retraced and analyzed by a second
blinded observer, the coefficient of variation is within 5%.
Similar tracing , digitizing and integrating of slice data were
performed on the postmortem overlays.
Left ventricular mass estimate. The volume of left ven-
tricular myocardial mass was also calculated from the un-
gated images and the postmortem overlays. This was ac-
complished by planimetry of the left ventricular myocardium
from the apex to the level of the outflow tract as previously
described (10). The total muscle mass derived from com-
puted tomography correlated well with postmortem values
in our study (r = 0.91, n = 21) . Noninfarcted mass was
derived by subtracting infarct mass from total mass. The
infarct volume was then divided by the volume of left ven-
tricular mass yielding the percent of myocardium that was
infarcted. All myocardial measurements were converted to
mass assuming a density of 1.05 g/crrr' .
In six additional dogs. the computed tomographic and
thallium planar measures of myocardial perfusion were
compared. The animals were anesthetized and coronary oc-
clusion was performed in the scanner, and 30 minutes later,
I to 1.3 mCi of thallium-201 was administered intrave-
nously . In each animal , the same vessel (left anterior de-
scending coronary artery) was occluded: IO minutes after
thallium-20 I was administered, contrast medium was given
as an infusion (identical to the technique in the present study)
and cross-sectional scans of 1 ern in depth were obtained.
The vertical axis of the scans was aligned with the long axis
of the left ventricle. Images were obtained from the apex
to the base of the heart. Once the computed tomographic
scans were reconstructed, the animal was killed by admin-
istering intravenous potassium chloride. The heart was re-
moved and sectioned (1 cm depth) along the long axis of
the left ventricle (analogous to the image acquisition) . Each
postmortem section was imaged with a standard gamma
camera peaked and windowed for thallium-20 I. Both the
X-ray computed tomographic and radionuclide (ungated)
images were printed on transparent film along with spatial
calibration markers . In each animal, the perfusion defect
was assessed by planimetry (region of reduced attenuation
on computed tomography or reduced radionuclide emissions
on thallium scintigrams). The volume of the computed tomo-
graphic and radionuclide data was obtained by summing
the cross-sectional volumes (each slice was I cm and the ge-
ometryofeach section was assumed to be cylindrical) from the
apex to base of the heart. The perfusion data from both tech-
niquescorrelated well (r = 0 .96 ,p<0.01).
The relation between the initial perfusion defect, analogous
to an area of jeopardy, and the subsequent volume of calcu-
lated infarction was analyzed over time by the ratio :
I f t/i d . Volume of enhanced defectnarc jeopar y ratio =
Volume of perfusion defect'
This calculation was made for each sampling point during
the study.
Study 2
In an additional 12 dogs , the identical surgical protocol
was followed. Two groups were again identified with six
dogs each in the control and propranolol-treated groups.
However, in contrast to the first study, each animal was
killed 4 days after occlusion of the left anterior descending
coronary artery. Once again a perfusion zone was deter-
mined immediately after coronary occlusion. At postmortem
examination, the infarct zone was easily visualized and five
to six transmural samples of approximately I cc volume
were taken from the normal and infarct segments. The heart
was sectioned and planimetry performed for calculated in-
farct zone as a percent of total muscle mass as previously
described (8-10,13,14).
The samples were weighed (Mettlars Beam Balance),
gently dried for 7 days in a vacuum oven and then re-
weighed. Multiple weighings within the 7 day interval en-
sured a stable dry weight. The water content of the infarct
tissue (Iwet weight - dry weightl/wet weight) was then
normal ized to the values derived from control segments of
myocardium from the noninfarct zone.
Statistics. All data are given as group mean ± I stand-
ard deviation. Repeated measures analysis of variance was
used to evaluate all raw data over time (15) . The correlations
of the final computed tomographic infarct size and total left
ventricular mass with the pathologic specimen were ob-
tained with a least-squares fit using linear regression analysis
(see Methods). Groups were compared at the same time
period with standard analysis of variance.
Results
Acute hemodynamic changes. After coronary occlu-
sion, propranolol treatment resulted in an initial increase in
mean left atrial pressure (6.2 ± 1.3 from 2.6 ± 1.2 mm
Hg, p < 0.01) when compared with values in group 1
(control group) (3.1 ± 1.0 mm Hg, p < 0.05) along with
a significant reduction in heart rate ( 129 ± 24 from 112 ±
23 beats/min , p < 0 .0 I versus group I, 132 ± 24 beats/min
in the control group) and mean arterial pressure (102 ± 15
from 119 ± 15 mm Hg, p < 0.05 versus 117 ± 14 mm
Hg in the control group). At each scanning sequence, the
heart rate for each group was measured. The heart rate from
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Table 1. Initial Myocardial Perfusion Defect Table 3. Water Content of Infarct Segments (4 day infarcts)
No. of Defect/Total LV Mass
Dogs Defect (g) Ratio
Group I
(control)
Group 2
(propranolol-treated)
II
10
16.9 ± 7.3
18.0 ± 9.9
21.4 ± 6.9
20.4 + 9.3
Normal Infarct Ratio
Group I 75.5 ± \.6 84.4 ± :U 1.12 ± 0.06
(control)
Group 2 76.0 ± 1.3 85.0 ± 3.5 1.12 ± 0.09
(propranolol-treated)
All values are given as mean ± standard deviation.
All values are given as mean ± standard deviation. LV = left ventricular.
the propranolol-treated group was 10 ::!:: 3 beats/min slower
during the day 4 scan (p < 0.01) when compared with that
in the control group. During all subsequent scans, the heart
rates from each group were similar.
Scan data. The initial perfusion defects were similar in
both groups, and each perfusion defect represented a con-
sistent proportion of the total left ventricular mass (Fig. 1.
Table 1). The serial changes in infarct size in each group
are shown in Table 2, and presented as a percent of non-
infarct mass and as a ratio with the initial perfusion defect.
Statistically significant reductions in infarct size as a percent
of left ventricular mass were noted at 4,9 and 30 days. The
"infarct/jeopardy" ratio (infarct/perfusion defect) was pro-
gressively smaller when comparing the control group with
the propranolol-treated group at day 4. This disparity altered
as time passed, with the propranolol-treated group dem-
onstrating the smallest infarct/jeopardy ratio on days 28 to
32 when compared with the control group (mean reduction
of 29%, p < 0.01 versus control group).
When the second group of 4 day infarct animals was
evaluated, the animals treated with propranolol (group 2)
demonstrated similar bulk water content when compared
with control animals (group I) (Table 3).
Compensatory hypertrophy. Both groups developed
compensatory hypertrophy by 30 days after initial infarction
(Table 4). Finally, the correlation of postmortem and scan
infarct size estimates was excellent (r = 0.91, SEE = 2.6
g). The postmortem (9.7 ::!:: 4.1 g) and scan infarct
(10.1 ::!:: 3.9) estimates did not differ.
Discussion
Because few studies directed at evaluating the change in
myocardial infarct size are available (10) and the reduction
of infarct size is an important goal in the clinical manage-
ment of acute ischemic injury (7,18), this study was devised
to examine the effects of a pharmacologic agent (propran-
olol) on the natural progress of infarct size and compensatory
hypertrophy. Ungated, contrast-enhanced computed tomog-
raphy was the technique utilized to study infarct size and
muscle mass over time. Both measurements have been re-
peatedly validated in experimental canine infarcts in this
and other laboratories (4-10).
Beta-adrenergic blockade in infarction. Beta-adren-
ergic blocking agents have been proposed as possible agents
for infarct size limitation because they have negative ino-
tropic and chronotropic effects (10), reduce myocardial ox-
ygen consumption (18) and alter myocardial perfusion char-
acteristics (19). Intravenous propranolol (as administered
chronically in this study for 7 days) is known to reduce
cardiac output and systemic pressure as well as contractile
performance (18,20). Both practolol and propranolol have
been shown to reduce ST segment elevation and myocardial
loss of creatine kinase (21,22); they have also been shown
to reduce infarct size by some (23,24). but not all (25)
investigators. Nonetheless, many studies (3) have demon-
strated a decrease in long-term morbidity and mortality after
the administration of beta-adrenergic blocking agents in pa-
tients with myocardial infarction. The relation to long-term
control of ischemia, perfusion and arrhythmias may con-
tribute to these findings. However, in the current study, we
Table 2. Infarct Size Changes
o Days 4 Days 9 Days 30 Days
% LV mass
Group I 21.4 ± 6.9 30.0 ± 10.1 19.9 ± 10.1 12.7 ± 4.6
(control)
Group 2 20.4 ± 93 24.1 ± 6.9 t 16.1 ± 6.3t 9.2 ± 4.8t
(propranolol-treated)
Infarct/jeopardy ratio
Group I 1.00 ± 0.00 \.62 ± 0.70 1.05 ± 0.35 0.68 ± 0.16
Group 2 1.00 ± 0.00 1.31 ± 0.47t 0.84 ± 0.01* 0.48 ± 0.28*
*p < 0.01 versus group I; tp < 0.05 versus group I. All values arc given as mean ± standard deviation.
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o Days 4 Days
% of Initial Total Muscle Mass
9 Days 30 Days
Group 1
Group 2
78.6 ± 12.3
79.6 ± 13.6
80.6 ± 13.3
82.5 ± 18.6
90.2 ± 16.1*
89.0 ± 15.5*
95.9 ± 18.0t
93.7 ± 17.lt
% ~ vs. Initial Total Muscle Mass
Group 1
Group 2
2.5 ± 5.1
3.6 ± 3.6
14.8 ± 12.9
11.8 ± 15.3
22.0 ± 14.1
17.7 ± 17.4
*p < 0.01 vs. day 0; tp < 0.005 vs. day O.
found significant reductions in infarct size resulting from
the administration of propranolol. It is possible that admin-
istered in a more continuous or sustained fashion (rather
than twice daily in a brief 20 minute infusion), beta-adren-
ergic blocking agents can indeed be shown to limit infarct
size even further. In the current study, the effects of general
anesthesia may have minimized the beta-adrenergic block-
ing effects of the drug. It is possible that the membrane-
stabilizing effects of the drug contributed to myocardial
salvage (particularly at the doses used in this study).
Infarction and edema. From the data derived from study
2, it appeared that the reduction in infarct size (or infarct
jeopardy zone) 4 days after coronary occlusion after pro-
pranolol administration was not related to a reduction in the
water content in the infarct segment. These data suggest
that edema control was not an important component in in-
farct size with beta-adrenergic blockade. The natural pro-
gression of infarct size shown in this and a previous study
(10) may help to create a reference frame for assessing the
usefulness of therapeutic interventions designed to modify
infarct size. We found a significant increase in infarct size
4 days after coronary ligation predominantly due to edema
formation. In a study of 4 and 28 days old infarcts, Reimer
and Jennings (26) noted that early enlargement (4 days) of
infarct volume was secondary to edema formation, hem-
orrhage and cellular infiltration. We also observed that the
volume of the infarct progressively diminished in size after
4 days, with stabilization occurring around 3 to 4 weeks
after coronary ligation. Moreover, the amount of bulk water
in the infarct increases for the first several days after myo-
cardial infarction, after which time water content decreases
(and fibrous tissue increases) (27). Carlsson et al. (28) found
a similar pattern of infarct shrinkage at 3 to 4 weeks.
Clinical implications. We conclude that computed to-
mography is an accurate technique for measuring and study-
Figure 1. Images from one cross section of myocardial infarct on
day I (A) (perfusion defect), day 9 (B) and day 30 (C) after
coronary occlusion. The dotted line outlines the perfusion defect
(A) or the infarcted tissue (B) and (C) on the section displayed.
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ing changes in myocardial infarct size and left ventricular
muscle mass over time in experimental animals. In partic-
ular, its ability to determine the effects of drugs on infarct
size and compensatory increases in left ventricular mass may
prove clinically important in defining high and low risk
patient groups. This may be particularly true when cine
computed tomography is available. In the present canine
study. the utility of administering propranolol to reduce
infarct size has been examined. Although caution is advised
in the clinical application of these results, it is apparent that
studies designed to show the long-term reduction of infarct
size must take into account the natural and somewhat vari-
able regression of quantitative infarct size.
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